Funding for this research was provided by:
BC Children's Hospital Research Institute
Received: 22 May 2020
Accepted: 5 October 2020
First Online: 14 October 2020
Ethics approval and consent to participate
: Ethics approval was obtained from the University of British Columbia Children’s and Women’s Research Ethics Board. Consent to participate was obtained from all study participants.
: Not applicable.
: JJ, LS, and EH declare that they have no competing interests. VA has been an advisory board member at Avir Pharma. HK has received funding from Regeneron Pharmaceuticals and Adare Pharmaceuticals. ESC has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis; is a member of the healthcare advisory board for Food Allergy Canada; was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention; was co-lead of the CSACI oral immunotherapy guidelines, and was a member of the committee for the American Gastroenterological Association & AAAAI/ACAAI Joint Task Force guidelines on the management of eosinophilic esophagitis.